BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10643978)

  • 1. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors.
    Ginn PE; Fox LE; Brower JC; Gaskin A; Kurzman ID; Kubilis PS
    Vet Pathol; 2000 Jan; 37(1):33-9. PubMed ID: 10643978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors.
    Jaffe MH; Hosgood G; Taylor HW; Kerwin SC; Hedlund CS; Lopez MK; Davidson JR; Miller DM; Paranjpe M
    Vet Pathol; 2000 Jan; 37(1):40-6. PubMed ID: 10643979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors.
    Wolf JC; Ginn PE; Homer B; Fox LE; Kurzman ID
    Vet Pathol; 1997 Sep; 34(5):394-404. PubMed ID: 9381650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome.
    Camus MS; Priest HL; Koehler JW; Driskell EA; Rakich PM; Ilha MR; Krimer PM
    Vet Pathol; 2016 Nov; 53(6):1117-1123. PubMed ID: 27034386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs.
    Patnaik AK; Ehler WJ; MacEwen EG
    Vet Pathol; 1984 Sep; 21(5):469-74. PubMed ID: 6435301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
    Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
    Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001).
    Gieger TL; Théon AP; Werner JA; McEntee MC; Rassnick KM; DeCock HE
    J Vet Intern Med; 2003; 17(5):687-92. PubMed ID: 14529136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
    Abadie JJ; Amardeilh MA; Delverdier ME
    J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs.
    Gamblin RM; Sagartz JE; Couto CG
    Am J Vet Res; 1997 Aug; 58(8):857-63. PubMed ID: 9256970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of canine mast cell tumors: a comparison of three methods.
    Simoes JP; Schoning P; Butine M
    Vet Pathol; 1994 Nov; 31(6):637-47. PubMed ID: 7863578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
    Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
    Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog.
    Preziosi R; Morini M; Sarli G
    J Vet Diagn Invest; 2004 Nov; 16(6):554-61. PubMed ID: 15586571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphometry of canine cutaneous mast cell tumors.
    Strefezzi Rde F; Xavier JG; Catão-Dias JL
    Vet Pathol; 2003 May; 40(3):268-75. PubMed ID: 12724567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases.
    Michels GM; Knapp DW; DeNicola DB; Glickman N; Bonney P
    J Am Anim Hosp Assoc; 2002; 38(5):458-66. PubMed ID: 12220031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998).
    Hahn KA; King GK; Carreras JK
    J Am Vet Med Assoc; 2004 Jan; 224(1):79-82. PubMed ID: 14710881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors.
    Book AP; Fidel J; Wills T; Bryan J; Sellon R; Mattoon J
    Vet Radiol Ultrasound; 2011; 52(5):548-54. PubMed ID: 21689203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
    Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL
    J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).
    Sfiligoi G; Rassnick KM; Scarlett JM; Northrup NC; Gieger TL
    J Am Vet Med Assoc; 2005 Apr; 226(8):1368-74. PubMed ID: 15844431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs.
    Kravis LD; Vail DM; Kisseberth WC; Ogilvie GK; Volk LM
    J Am Vet Med Assoc; 1996 Oct; 209(8):1418-20. PubMed ID: 8870737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.